Crystale Purvis Cooper1, Mona Saraiya2. 1. Soltera Center for Cancer Prevention and Control, Tucson, AZ 85704, United States. 2. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30341, United States. Electronic address: msaraiya@cdc.gov.
Abstract
OBJECTIVE: To investigate the HPV testing recommendations of US physicians who perform cervical cancer screening. METHODS: Data from the 2015 DocStyles survey of U.S. health care providers were analyzed using multivariate logistic regression to identify provider characteristics associated with routine recommendation of primary HPV testing for average-risk, asymptomatic women ≥30years old. The analysis was limited to primary care physicians and obstetrician-gynecologists who performed cervical cancer screening (N=843). RESULTS: Primary HPV testing for average-risk, asymptomatic women ≥30years old was recommended by 40.8% of physicians who performed cervical cancer screening, and 90.1% of these providers recommended primary HPV testing for women of all ages. The screening intervals most commonly recommended for primary HPV testing with average-risk, asymptomatic women ≥30years old were every 3years (35.5%) and annually (30.2%). Physicians who reported that patient HPV vaccination status influenced their cervical cancer screening practices were almost four times more likely to recommend primary HPV testing for average-risk, asymptomatic women ≥30years old than other providers (Adj OR=3.96, 95% CI=2.82-5.57). CONCLUSION: Many US physicians recommended primary HPV testing for women of all ages, contrary to guidelines which limit this screening approach to women ≥25years old. The association between provider recommendation of primary HPV testing and patient HPV vaccination status may be due to anticipated reductions in the most oncogenic HPV types among vaccinated women. Published by Elsevier Inc.
OBJECTIVE: To investigate the HPV testing recommendations of US physicians who perform cervical cancer screening. METHODS: Data from the 2015 DocStyles survey of U.S. health care providers were analyzed using multivariate logistic regression to identify provider characteristics associated with routine recommendation of primary HPV testing for average-risk, asymptomatic women ≥30years old. The analysis was limited to primary care physicians and obstetrician-gynecologists who performed cervical cancer screening (N=843). RESULTS: Primary HPV testing for average-risk, asymptomatic women ≥30years old was recommended by 40.8% of physicians who performed cervical cancer screening, and 90.1% of these providers recommended primary HPV testing for women of all ages. The screening intervals most commonly recommended for primary HPV testing with average-risk, asymptomatic women ≥30years old were every 3years (35.5%) and annually (30.2%). Physicians who reported that patientHPV vaccination status influenced their cervical cancer screening practices were almost four times more likely to recommend primary HPV testing for average-risk, asymptomatic women ≥30years old than other providers (Adj OR=3.96, 95% CI=2.82-5.57). CONCLUSION: Many US physicians recommended primary HPV testing for women of all ages, contrary to guidelines which limit this screening approach to women ≥25years old. The association between provider recommendation of primary HPV testing and patientHPV vaccination status may be due to anticipated reductions in the most oncogenic HPV types among vaccinated women. Published by Elsevier Inc.
Entities:
Keywords:
Cervical cancer screening; HPV testing; Providers; United States
Authors: Warner K Huh; Kevin A Ault; David Chelmow; Diane D Davey; Robert A Goulart; Francisco A R Garcia; Walter K Kinney; L Stewart Massad; Edward J Mayeaux; Debbie Saslow; Mark Schiffman; Nicolas Wentzensen; Herschel W Lawson; Mark H Einstein Journal: Gynecol Oncol Date: 2015-01-08 Impact factor: 5.482
Authors: Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers Journal: CA Cancer J Clin Date: 2012-03-14 Impact factor: 508.702
Authors: Julia Ml Brotherton; Dorota M Gertig; Cathryn May; Genevieve Chappell; Marion Saville Journal: Med J Aust Date: 2016-03-21 Impact factor: 7.738
Authors: Joakim Dillner; Matejka Rebolj; Philippe Birembaut; Karl-Ulrich Petry; Anne Szarewski; Christian Munk; Silvia de Sanjose; Pontus Naucler; Belen Lloveras; Susanne Kjaer; Jack Cuzick; Marjolein van Ballegooijen; Christine Clavel; Thomas Iftner Journal: BMJ Date: 2008-10-13
Authors: Steffie K Naber; Inge M C M de Kok; Suzette M Matthijsse; Marjolein van Ballegooijen Journal: Cancer Causes Control Date: 2016-03-12 Impact factor: 2.506
Authors: Kathy L MacLaughlin; Robert M Jacobson; Jennifer L St Sauver; Gregory D Jenkins; Chun Fan; Lila J Finney Rutten Journal: Womens Health Rep (New Rochelle) Date: 2022-01-07
Authors: Adana A M Llanos; Jennifer Tsui; David Rotter; Lindsey Toler; Antoinette M Stroup Journal: BMC Womens Health Date: 2018-10-03 Impact factor: 2.809